Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442354 | 0.77 | NOTUM (0.38) | NOTUMPOLBNPSR1ALDH1A1LMNA | |
| SCHEMBL13440540 | 0.72 | NOTUM (0.47) | NOTUMPOLBALDH1A1LMNANPC1 | |
| SCHEMBL29832123 | 0.71 | OPRM1 (0.34) | POLBNPSR1 | |
| SCHEMBL28656798 | 0.71 | OPRM1 (0.34) | POLBNPSR1 | |
| SCHEMBL21931405 | 0.68 | ALDH1A1 (0.47) | NOTUMPOLBNPSR1ALDH1A1LMNA | |
| SCHEMBL4379145 | 0.67 | ALDH1A1 (0.47) | NOTUMPOLBNPSR1ALDH1A1MEN1 | |
| SCHEMBL21931406 | 0.67 | LMNA (0.46) | NOTUMPOLBNPSR1ALDH1A1LMNA | |
| SCHEMBL13442352 | 0.66 | TYMS (0.36) | NOTUMPOLBNPSR1ALDH1A1NPC1 | |
| SCHEMBL13442353 | 0.66 | TSHR (0.38) | POLBNPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19181866 | 0.65 | KCNH2 (0.33) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069380-A1 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069380-A1 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. | 2010-03-18 | — | — | US | disclosed |
| WO-2008127274-A2 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069380-A1 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | NSUN3, TARBP1, TRMT1 | NOTUM 3574/4885POLB 655/4885NPSR1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.